A Potential Shift In FDA's Approach To Drug Trial Design
On Jan. 9, the U.S. Food and Drug Administration issued draft guidance clarifying how Bayesian approaches may be used in clinical trials to support regulatory decision-making. It reflects the agency's continued...To view the full article, register now.
Already a subscriber? Click here to view full article